Insulin-like growth factor-I (IGF-I) immunoreactivity in the Alzheimer's disease temporal cortex and hippocampus.
IGF-I has been shown to enhance neuronal survival and inhibit apoptosis. IGF-I immunoreactivity was examined in the Alzheimer's disease and normal post-mortem human hippocampus and temporal cortex to determine whether IGF-I protein levels are altered in response to neurodegeneration. IGF-I immunoreactivity was induced in a subpopulation of GFAP-immunopositive astroglia in the Alzheimer's disease temporal cortex. These observations raise the possibility that IGF-I has a neuroprotective role in the Alzheimer's disease brain.
Connor
B
B
Department of Pharmacology, Faculty of Medicine and Health Science, University of Auckland, New Zealand.
Beilharz
E J
EJ
Williams
C
C
Synek
B
B
Gluckman
P D
PD
Faull
R L
RL
Dragunow
M
M
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000378:metabolism / Q000473:pathology*; D000911:Antibodies, Monoclonal; D001253:Astrocytes / Q000166:cytology / Q000378:metabolism / Q000473:pathology; D003429:Cross Reactions; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000032:analysis; D006624:Hippocampus / Q000166:cytology / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D007334:Insulin-Like Growth Factor I / Q000032:analysis* / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D009474:Neurons / Q000166:cytology / Q000378:metabolism / Q000473:pathology; D012016:Reference Values; D013702:Temporal Lobe / Q000166:cytology / Q000378:metabolism / Q000473:pathology*
D000911:Antibodies, Monoclonal; D005904:Glial Fibrillary Acidic Protein; D007334:Insulin-Like Growth Factor I